Slap on the wrist
If symptoms return before your scheduled injection, contact your GP to discuss your treatment schedule
Tanzilli G, Truscelli G, Arrivi A, et al
Recalls & Warnings December 08, 2017 Limbrel Capsules for Osteoarthritis Linked With Potentially Life-Threatening Health Risk, FDA Warns On December 4, 2017, the FDA urged consumers not to take Limbrel (Primus Pharmaceuticals), a capsule marketed to manage the metabolic processes associated with osteoarthritis, because it has been associated with serious adverse events, including drug-induced liver injury and a lung
Tirzepatide has been approved for T2D management - the mean HbA1c reduction in SURPASS programme ranged between 1.9 and 2.6% across the trials and 4069% of participants achieved 10% WL with the higher doses (10 and 15 mg), despite that there was no additional support for lifestyle intervention [16, 43]
There's no doubt in my mind that that connection is there